Altimmune ALT
NASDAQ ALT
$2.97 +0.01 (+0.27%)
As of: Sep 29, 2026 · 3:59 PM EDT

Altimmune (ALT) Cash from Restructuring (2015 - 2016)

Updated

Altimmune's Cash from Restructuring came in at -$67,307 for Q3 2016, compared with $10,152 a year earlier.

Analysis

Altimmune (ALT) Cash from Restructuring (2015 - 2016) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Altimmune 575.64 Mn 575.64 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2016 -67,307.00
Sep 30, 2015 10,152.00
API Access

Altimmune Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ALT&period=max&api_key=YOUR_API_KEY